TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC

描述(改编自申请人的摘要)：在 迅速扩大新的非典型抗精神病药物的使用 (奥氮平、利培酮、奎硫平)是声称非典型 抗精神病药物与较低的发病风险有关。 迟发性运动障碍的发生率比较老的传统药物要高。这一索赔是否 具有重要的临床、法医学和药物经济学意义。 临床前研究为为什么较新的非典型肺炎提供了可信的理由 药物治疗迟发性运动障碍的风险可能比常规药物低； 然而，到目前为止，只有一家公司直接解决了它们较低的风险。 发表了一项老年人对照疗效试验和一项研究。目的 本申请的目的是通过以下方式为这些研究提供补充数据 采用自然主义的关联研究方法。 目前的项目建议调查持续性肺炎的发生率 在服用非典型抗精神病药物的患者中，单独服用或在 与常规用药相结合，其发病率低于 单独服用常规抗精神病药物的患者。此外，我们还将 调查其他风险因素，包括情感障碍的诊断 服用非典型抗精神病药物患者TD发生率的相关性研究 用药情况，探讨发病病例的预后和病程。 为了达到这些目标，一个新的样本，大约838名患者免费 持续的TD将从该医院的门诊人口中招募 康涅狄格州精神卫生中心(CMHC)。这些患者将接受后续治疗 一年两次考试，平均3.25年。 CMHC是NIMH之前赞助的一项研究(MH39665)的所在地 年在CMHC门诊人群中确定新的TD病例的发病率 1985年7月1日至1986年12月31日期间确定的样本，随后进行了 长达5年。在同一地点存在以前的样本提供了一个 有用的附加比较组。方法包括样品确证和 TD评估是紧密仿照原著进行的。

DESCRIPTION (Adapted from the Applicant's Abstract): Among the drivers of the rapidly expanding use of the newer atypical antipsychotic medications (olanzapine, risperidone, quetiapine) is the claim that the atypical antipsychotic medications are associated with a lower risk for the development of tardive dyskinesia than are the older conventional drugs. Whether this claim is true is of great clinical, medicolegal, and pharmacoeconomic importance. Preclinical studies provide a credible rationale for why the newer atypical medications may have a lower risk of tardive dyskinesia than the conventionals; however, their lower risk has been addressed so far directly by only one published controlled efficacy trial and one study in the elderly. The purpose of the present application is to provide complementary data to these studies by using a naturalistic incidence study method. The current project proposes to investigate whether the incidence of persistent TD among patients taking atypical antipsychotic medications, alone or in combination with conventional medications, is lower than the incidence among patients taking conventional antipsychotics alone. In addition we will investigate other risk factors including affective disorder diagnosis associated with the incidence of TD in patients taking atypical antipsychotic medications and explore the prognosis and course of incident cases. To address these aims, a new sample of approximately 838 patients free of persistent TD will be recruited from the outpatient population of the Connecticut Mental Health Center (CMHC). These patients will be followed with biannual examinations for an average of 3.25 years. The CMHC was the site of a previous NIMH sponsored study (MH39665) that determined the incidence of new TD cases in the CMHC outpatient population from a sample identified between July 1, 1985 and December 31, 1986 and followed for up to 5 years. The existence of a previous sample at the same site provides a useful additional comparison group. Methods including sample ascertainment and TD assessment are closely modeled after the original work.